The Interchangeability and Substitutability Conundrum: Time for Convergence
The first blog post for this year was on interchangeability. In it I announced that SAHPRA has decided that biosimilars will be interchangeable with its reference products...
Setting specifications for Dissolution of Immediate Release Solid Oral Dosage Forms The importance of the biobatch
The approval of Rybelsus®, which contains the GLP-1 agonist, semaglutide, by the EMA in April 20201 is of special interest because, unlike other biologics that are mostly...
Setting specifications for Dissolution of Immediate Release Solid Oral Dosage Forms The importance of the biobatch
The approval of Rybelsus®, which contains the GLP-1 agonist, semaglutide, by the EMA in April 20201 is of special interest because, unlike other biologics that are mostly...
Join the Biosimilars Movement | Nov 5 2021
We want to hear from you! This #GlobalBiosimilarsWeek, share your stories, information and educational resources, and initiatives so we can build a better world for biosimilars—...
Building a Better Future with Biosimilars | Nov 4 2021
Greater access to #biosimilar = more care for more patients. https://bit.ly/GlobalBiosimilarsWeek #GlobalBiosimilarsWeek #Biosimilars are the key to building a better future for...
Biosimilars and Patient Benefits | Nov 3 2021
With the lower treatment costs achieved thanks to #biosimilars, we can re-invest in other health care services - like childcare, eldercare, mental health services, research and...
The Biosimilars Road Ahead | Nov 2 2021
The continued development of #biosimilars will promote health equity and access to care for millions of patients worldwide. Join the conversation with #GlobalBiosimilarsWeek....
Today’s Biosimilars Landscape | Nov 1 2021
Q: What are #biosimilars? A: Biosimilars are biologic medicines that are highly similar to a previously approved reference biologic. Biosimilars provide an opportunity to create...